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Abstract  
Introduction: Plasmablastic lymphoma, a rare and aggressive form of Non-Hodgkins lymphoma, rarely presents as a 
retroperitoneal mass.  There are no case reports in the literature of plasmablastic lymphoma presenting in living, HIV-negative 
patient status post liver transplantation. 
Presentation of Case: We report the case of a 63 year-old HIV-negative male status post liver transplant who presented with 
weakness and obstructive uropathy. Imaging showed a large mass in the retroperitonium. Biopsy revealed plasmablastic 
lymphoma. CHOP therapy was initiated and after six cycles, the retroperitoneal mass regressed in size; however, cytology from 
pleural fluid revealed that the disease remained. It has been 9 months since initial diagnosis and he was started on salvage 
chemotherapy with ESHAP however he subsequently developed a treatment related myelodysplastic syndrome with trisomy 12. 
Conclusions: The present case is used to explore the presentation and treatment of plasmablastic lymphoma, and to review the 
literature concerning the rarity of this disease in the setting of a HIV-negative patient status post solid organ transplantation. 
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Introduction 
Plasmablastic lymphoma (PBL) is an aggressive and 
rare form of Non-Hodgkin’s Diffuse B cell 
lymphoma [1-7, 9-12, 15]. This disease is usually 
considered an acquired immunodeficiency syndrome 
(AIDS)-related lymphoma but it has also been seen 
in Human Immunodeficiency Virus (HIV)-negative 
patients [1-6, 9, 10]. PBL has a strong association 
with the Epstein Barr Virus [6-8]. It has a 
predilection for the oral cavity however extra-oral 
sites including central nervous system, lung, liver, 
small bowel, testis and lymph nodes have been 
reported [1, 6, 9-11].  
There have been two reported cases of 
plasmablastic lymphoma presenting as a 
retroperitoneal mass [10, 11]. The first case involved 
a HIV-positive American male and the second case 
described a HIV-negative male from Japan whose 
diagnosis was made at autopsy. In this case report we 
describe the first known report of plasmablastic 
lymphoma in a living, American, HIV-negative male, 
status-post solid organ transplantation who presented 
with weakness and obstructive uropathy secondary 
to a retroperitoneal mass. 
Case presentation 
A 63-year-old male presented to the emergency 
department with generalized weakness, urinary 
retention and diarrhea.  His past medical history is 
notable for end stage liver disease secondary to 
hepatitis C status post orthotopic liver transplant 
approximately one year ago treated with Tacrolimus, 
Ribavirin, and Peginterferon alpha 2a.  Work up 
prior to transplantation revealed previous exposure to 
the Epstein Barr Virus. He denied any current 
tobacco, alcohol or recreational drug use however, he 
did admit to drinking heavily from age 20-27 
drinking a 6 pack per day.   
On physical exam vital signs were stable and 
physical exam was unremarkable except for dry 
mucous membranes, poor skin turgor and an 
enlarged prostate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 CT Abdomen/Pelvis illustrating a 11.95 cm retroperitoneal mass in the right external iliac region. 
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Laboratory findings revealed pancytopenia, 
hyponatremia, and BUN of 48 mg/dL and creatinine 
of 4.8 mg/dL. A foley catheter was placed and 
drained 1500 ml of bloody urine. Intravenous fluid 
hydration was started immediately. He was admitted 
for evaluation of acute kidney injury and 
hematologic abnormalities.  A bladder ultrasound 
revealed a distended bladder, bladder wall thickening 
and an enlarged and heterogenous prostate 
compatible with prostate hypertrophy. Computer 
Tomography (CT) of the abdomen and pelvis 
showed multiple large retroperitoneal masses, largest 
mass (11.95 cm in diameter) was in the right external 
iliac region (Figure 1). Histopathology of the pelvic 
mass revealed plasmablastic B cell lymphoma that 
was CD138 strong +, CD3-, CD5-, CD10-, CD20-, 
CD23- CD30- CD79a+, CD117 weak +, Cyclin-D1-, 
Multiple Myeloma Oncogene-1+, Kappa-, Lambda+, 
Keratin-, Epithelial Membrane Antigen+, Placental 
Alkaline Phosphatase-, Human Herpes Virus 8- and 
Epstein Barr Virus+ (Figure 2).    
Immunohistochemical stains were negative for 
activin receptor-like kinase 1 (ALK1).  A bone 
marrow biopsy showed no evidence of lymphoma 
involvement and a markedly hypocellular marrow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 A: Hematoxylin and Eosin, 40x.  Tumor is comprised of large cells with scant cytoplasm, nuclei with 
dispersed (fine) reticular chromatin with minimal to no chromatin clumping and 1 or more large nucleoli 
B: CD138, 20x.  Tumor cells are diffusely immunoreactive for CD138 by immunohistochemistry. 
C: EBER, 10x.  Tumor cells express Epstein Barr Virus encoded RNA (EBER) by in-situ hybridization. 
 
An infusaport was placed and a mutli gated 
acquisition scan (MUGA scan) was done prior to 
starting treatment.  The patient was started on 
Cyclophosphamide, Doxorubicin, Vincristine and 
Prednisone (CHOP).   After the second cycle of 
chemotherapy, a staging Positron Emission 
Tomography- Computed Tomography (PET/CT) 
showed no evidence for retroperitoneal uptake and 
the pelvic sidewall mass was approximately 6.5 cm. 
Standardized Uptake Value (SUV) was only mildly 
elevated up to 2.6 (Figure 3). 
Approximately 6 months later after completion of 
six cycles of CHOP therapy, the patient received a 
restaging PET/CT which revealed a significant 
decrease in size and SUV activity in the right pelvic 
sidewall mass and no evidence for new lesions. A 
new large, left pleural effusion was discovered 
(Figure 3). Cytology from the pleural fluid revealed 
plasmablastic lymphoma with 71% of all nucleated 
element being cytoplasmic lambda monoclonal 
plasma cells. The patient was started on salvage 
chemotherapy with ESHAP (Etopiside, 
methylprednisolone, cytarabine and cisplatin).  
  
 
Ivy Union Publishing | http: //www.ivyunion.org February 20, 2014 | Volume 2 | Issue 1  
Katz H et al. American Journal of Cancer Case Reports 2014, 2:18-23 Page 4 of 6 
 
 
 
 
 
 
 
 
 
 
Figure 3 A: Initial PET/CT showing the pelvic sidewall mass measuring approximately 6.5 cm 
B: Restaging PET/CT showing a significant decrease in size and SUV activity in the right pelvic sidewall mass and no 
evidence for new lesions 
Discussion 
Plasmablastic Lymphoma is a rare aggressive variant 
of diffuse large B cell Non-Hodgkin’s lymphoma. 
Tumor cells are comprised of terminal B cells that 
have well differentiated plasma markers such as 
CD138 and minimal or absent expression of B cell 
markers CD45, CD20, and CD79a [1-5]. EBV 
infection has been observed in 74% of published 
PBL cases [1]. Epstein Barr Virus Encoded RNA 
In-Situ Hybridization (EBER-ISH) has a positive 
predictive value of close to 100% in HIV-positive 
PBL patients.  Therefore, it has been suggested to 
use EBER-ISH to aid in the diagnosis of PBL [6-8]. 
According to Castillo et al., Patients who had 
HIV-negative PBL have lower rates of Epstein-Barr 
virus-encoded RNA expression than HIV-positive 
patients [6].   
Plasmablastic lymphoma accounts for 2.6% of all 
AIDS related lymphoma [1,7,10]. It has also been 
described in approximately 76 cases of HIV-negative 
patients, both immunocompromised from solid organ 
transplantation as well as in immunocompetent 
individuals [6]. Delecluse et al. reported PBL in 
HIV-positive patients is most often found in the oral 
cavity and was seen in 58% of cases [7]. In 
HIV-negative patients, oral cavity involvement is 
lower at 21% of the cases and is more likely to 
present with extra-oral sites. PBL has been found in 
the CNS, liver, lungs, testis, subcutaneous tissue of 
the arm, lymph nodes and retroperitoneum [9-12]. 
Sixteen cases have been described in literature 
associated with immunosuppression from anti 
rejection therapy after solid organ transplant (kidney, 
heart, lung, and pancreas) [14]. 
A literature review was performed using Pubmed 
confirmed the rarity of plasmablastic lymphoma 
presenting as a retroperitoneal mass. Only two cases 
have been reported.  Dholaria et al. described a case 
of PBL of the retroperitoneum in an HIV-positive 
patient and Takahashi et al. described a case of a 
HIV-negative male from Japan who was diagnosed 
at time of autopsy with plasmablastic lymphoma 
[10,11]. There has been no reported cases of 
plasmblastic lymphoma presenting as a 
retroperitoneal mass in a living, American, HIV 
negative patient. Furthermore, there are no reported 
cases of PBL status post liver transplantation in 
adults documented in literature. 
PBL is associated with early dissemination, poor 
response to therapy and limited survival [1-6, 9,11]. 
In HIV negative patients, overall survival is 
approximately 9 months [6,15]. The National 
Comprehensive Cancer Network (NCCN), 
recommends Hyper-CVAD (Cyclophosphomide, 
vincristine, doxorubicin, and dexamethasone 
alternating with high dose methotrexate and 
cytrabine), dose adjusted –EPOCH (etopiside, 
prednisone, vincristine,  cyclophosphamide, 
doxorubicin) or CODOX-M/IVAC 
(cyclophosphamide, vincristine, doxorubicin, high 
dose methotrexate, alternating with ifosfamide, 
etoposide, and high dose cytrabine) [15]. While 
NCCN guidelines state that CHOP therapy is not 
adequate, Castillo et al. reports more intensive 
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regimens have not shown a survival advantage when 
compared to CHOP therapy [13,15]. Our treatment 
plan is similar to one described by Jae Myung Cha et 
al. in an article titled, A case report with 
Plasmablastic Lymphoma of the jejunum, in which 
the patient was treated with six cycles of CHOP and 
salvage chemotherapy with ESHAP.  The patient 
had a survival of greater than 24 months [12]. In our 
case, the patient had a near complete response to 
CHOP chemotherapy with a rapid relapse in an 
extra-lymphatic site. He subsequently started on 
ESHAP but after one cycle developed refractory 
thrombocytopenia and was diagnosed with treatment 
related myelodysplasic syndrome with a trisomy 12. 
ESHAP has currently been stopped. More research is 
needed to establish better treatment guidelines to 
increase survival.   
This is the first case of plasmablastic lymphoma 
presenting as a retroperitoneal mass in a living, 
HIV-negative patient and is among one of the 
extremely rare cases of plasmablastic lymphoma 
diagnosed after solid organ transplantation. This case 
is the first described in literature status-post liver 
transplant in an adult.   
Conclusion 
In conclusion, the findings of this case suggest that 
plasmablastic lymphoma should be included in the 
differential diagnosis of patients who are status-post 
transplantation presenting with a retroperitoneal 
mass.  The course of this patient’s disease and care 
will be a useful addition to the current literature for 
determining the treatment and prognosis in 
HIV-negative patients presenting with PBL. 
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Written informed consent was obtained from the 
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